Comments
The stock of Sharon Bio-Medicine will remain in focus, as the company’s board meets on Tuesday to restructure the company’s debts. Due to fire in one of the plants in 2014 and non-availability of working capital, the management of the company feels, restructuring is the best option now for the company. The pharmaceuticals company has reported a loss of ₹103.37 crore on revenues of ₹237.93 crore for the quarter ended December 2014.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.